| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $31.7M | +26.9% |
| SG&A Expense | $17.4M | -6.3% |
| Operating Income | -$49.2M | -12.7% |
| Net Income | -$44.6M | -10.3% |
| EPS (Basic) | -$2.17 | +39.2% |
| EPS (Diluted) | -$2.17 | +39.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $162.8M | +311.3% |
| Short-term Investments | $7.5M | -71.2% |
| Current Assets | $172.2M | +150.6% |
| Total Assets | $181.5M | +129.8% |
| Current Liabilities | $11.0M | +78.3% |
| Total Liabilities | $14.3M | +34.7% |
| Stockholders' Equity | $167.1M | +144.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$35.8M | +4.7% |
| Capital Expenditures | $63K | +40.0% |
| Investing Cash Flow | $19.2M | -63.9% |
| Financing Cash Flow | $139.9M | — |
| Free Cash Flow | -$35.9M | +4.6% |